Form 4: Pfizer Director Shantanu Narayen Reports Acquisition of Phantom Stock Units
SEC Form 4 Filing
Director Shantanu Narayen reports acquisition of phantom stock units representing deferred director's compensation.
Summary
- On June 28, 2024, Shantanu Narayen, a director of Pfizer Inc. [PFE], acquired 1,786.991 phantom stock units.
- These units represent deferred director's compensation, including dividend equivalents.
- The units will be settled in cash or common stock at the director's election following retirement from the Board of Directors.
- The price of the underlying common stock was $27.98.
- Following the transaction, Narayen directly owns 146,478.861 derivative securities.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing indicating standard compensation practices, neither particularly positive nor negative.
Future Outlook
The phantom stock units will be settled in cash or common stock at the director's election following retirement from the Board of Directors.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding director compensation.
Key Dates
| Date | Description |
|---|---|
| 06/28/2024 | Date of transaction: Acquisition of phantom stock units. |
| 07/01/2024 | Date of signature on the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.